Cell and Gene Therapy World Asia (CGTWA) – 2023 – Sentosa, Singapore

Our CEO and co-founder, Ivan D. Horak, moderated a panel discussion on "Innovations and Opportunities in Cell and Gene therapy in the APAC region" at the 7th annual Cell and Gene Therapy World Asia 2023 conference (Singapore). This event showcased the dynamic and rapidly evolving Cell & Gene Therapy industry in the Asia-Pacific region.
Cell and Gene Therapy in the APAC region. The panelists, starting from the left, Christy Ma, CS0, SCG Cell therapy, Singapore, Silviu Itescu, CEO, Mesoblast, Australia, Ivan D Horak (Moderator), CEO & Founder, Tikva Allocell, Singapore and Xiaoping Cao, Senior Vice President, JW Therapeutics, China

The 7th annual Cell and Gene Therapy World Asia 2023 conference took place on the 14th and 15th of September at the Equarius Hotel, Resorts World Sentosa, Singapore. This event showcased the dynamic and rapidly evolving Cell & Gene Therapy industry in the Asia-Pacific region. The conference was designed to provide attendees with a unique platform to engage with key decision-makers from some of the most cutting-edge and innovative companies in the Cell & Gene Therapy field worldwide. It was a remarkable opportunity for businesses to position themselves at the forefront of this exciting industry, fostering collaboration, innovation, and growth.

Our CEO and co-founder, Ivan D. Horak,  assumed the role of moderator during the “Leadership Panel Discussion by APAC leaders: Innovations and Opportunities in Cell and Gene therapy in the APAC region” at the Cell and Gene Therapy World Asia 2023 conference. This panel provided a unique platform for top industry leaders to share insights and discuss the groundbreaking innovations and opportunities emerging in the field of cell and gene therapy throughout the Asia-Pacific region. As the session unfolded, our CEO not only facilitated the discussion but also took the opportunity to present Tikva Allocell’s ambitious pipeline. He outlined the company’s vision for combating solid tumors using Allogenic CAR-T cells, shedding light on the innovative approaches and research that Tikva Allocell is spearheading. Significant obstacles remain, including the complex tumor microenvironment, antigen selection, toxicities, costs, and resistance. Addressing these challenges and advancing research in this area is vital to improving the effectiveness of CAR-T therapy for solid tumors and expanding its accessibility to a broader patient population. In his presentation, Dr. Ivan Horak candidly addressed the challenges associated with treating patients afflicted by various forms of cancer, underscoring the importance of collaborative efforts and the numerous opportunities that exist in the ever-evolving landscape of cancer therapy.

Among the distinguished roster of speakers at the Cell and Gene Therapy World Asia 2023 conference, Xiaoping Cao, the Senior Vice President and Head of Tech-ops at JW Therapeutics in China, offered an enlightening and insightful presentation. Cao delved into Autologous CAR-T cell therapy Product Development, a field marked by groundbreaking advances. Cao shared his expertise on the strategies and methodologies involved in developing robust CAR-T cell products. He also highlighted the pivotal aspects of building a robust CMC (Chemistry, Manufacturing, and Control) infrastructure to ensure consistency and quality throughout the manufacturing process. Other speakers included Rosanne Dunn, the Chief Scientific Officer of Haemalogix in Australia, who delivered a captivating presentation, shedding light on her company’s pioneering pipeline. Her talk, titled “Specificity of KMA.CAR T cells against a novel B cell target called kappa myeloma antigen (KMA),” was both informative and innovative, as she discussed the development of KMA.CAR T cells, a groundbreaking approach to treating myeloma, a challenging form of blood cancer.

Sabry Hamza, PhD

Director, Product Development and Analytical Sciences

Sabry has biotech, biopharma and academic experience at Tessa Therapeutics, Merck, Chiron and the Genome Institute of Singapore. His specializes assay development and validation to support product development, manufacturing, and quality control. He is also experienced with regulatory agencies (FDA, EMA) on the submission process.

Share the Post:

Related Posts